Literature DB >> 28114268

Down-Regulation of miRNA-128 Contributes to Neuropathic Pain Following Spinal Cord Injury via Activation of P38.

Zhaoyun Yang1, Junmei Xu1, Rong Zhu1, Lei Liu1.   

Abstract

BACKGROUND Neuropathic pain (NPP) arises from a lesion or dysfunction of the somatosensory nervous system. Recent studies have demonstrated multiple microRNAs (miRNAs) play key roles in NPP development. This study aimed to investigate the effects of miR-128 on microglial cells. MATERIAL AND METHODS We established a compressive spinal cord injury (SCI) model and collected the spinal cord segment-derived conditioned medium (CM). We then measured the expression of miR-128 in the murine microglial cell line BV2 treated with CM-SCI or CM obtained from control (CM-NC). Furthermore, lentivirus production of miR-128 and scrambled control were transfected into BV2 cells, which were first treated with CM-SCI or CM-NC. Moreover, the effects of miR-128 on cell viability, M1/M2 microglial gene expression, inflammatory cytokines concentration, and the protein expression of P38 and phosphorylated P38 (P-P38) were investigated. RESULTS The expression of miR-128 was downregulated in murine microglial BV2 cells treated with CM-SCI. Overexpression of miR-128 markedly promoted the viability of murine microglial cells. In addition, miR-128 overexpression significantly decreased the expression levels of microglial M1 phenotypic markers CD86 and CD32, and increased the expression levels of M2 phenotypic markers Arg1 and CD206. Furthermore, miR-128 overexpression obviously decreased the concentration of TNF-α, IL-1β, and IL-6. We found that miR-128 overexpression significantly downregulated the expression levels of P38 andP-P38. CONCLUSIONS Our findings indicate that down-regulation of miR-128 in murine microglial cells may contribute to the development of NPP following SCI via activation of P38. MiR-128 may be a potential intervention target for NPP.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28114268      PMCID: PMC5282966          DOI: 10.12659/msm.898788

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


Background

Neuropathic pain (NPP) arises from a lesion or dysfunction of the somatosensory nervous system, adversely impacting quality of life [1,2]. A considerable proportion of patients with NPP have been observed to have an increased risk of social defect symptoms, including anxiety, depression, and suicidal ideation. In a significant number of patients, the treatment of NPP is inadequate and remains a great challenge [4-6]. A better understanding of the molecular mechanisms underlying NPP may lead to the development of more efficient therapeutics for patients. MicroRNAs (miRNAs), small non-coding RNAs, have attracted considerable attention recently due to their key role in a variety of neurological diseases [7,8]. miRNAs can regulate the expression of multiple genes by binding to 3′-untranslated region (3′-UTR) of target mRNAs [9]. Recent studies have showed that miRNAs function as critical mediators in the regulation of neuroinflammation and NPP [10-12]. Chen et al. showed that intrathecal miR-96 could alleviates NPP via inhibiting the expression of Nav1.3 in rats following chronic construction injury [13]. Favereaux et al. demonstrated that miR-103 was downregulated in neuropathic animals and implied that miR-103 might be a possible therapeutic target because intrathecal applications of miR-103 relieved neuropathic pain successfully [14]. It is also reported that miR-195 may be a potential target for therapy of NPP because increased miR-195 can aggravate NPP via inhibiting autophagy after peripheral nerve injury [15]. Aberrant miRNA expression may play key roles in NPP development; therefore, exploring more miRNAs involved in NPP will provide an avenue for elucidation the molecular mechanism or identification of potential therapeutic targets. However, little is known about the key miRNAs associated with NPP to data. In the present study we established a compressive spinal cord injury (SCI) model and collected the spinal cord segment-derived conditioned medium (CM). We then measured the expression of miR-128 in the murine microglial cell line BV2 treated with CM-SCI or CM obtained from control (CM-NC). Furthermore, lentivirus production of miR-128 and scrambled control were transfected into BV2 cells treated with CM-SCI or CM-NC to detect the effect of miR-128 overexpression. Our study aimed to investigate the biological functions of miR-128 on microglial cells, as well as to elucidate the regulatory mechanism underlying NPP.

Material and Methods

Animals

All the experiments were approved and reviewed by the Animal Care Committee of the Fourth Military Medical University. Male Sprague-Dawley rats (weighing 220–250 g) were obtained from the Experimental Animal Center of the Fourth Military Medical University and housed at a temperature 22–25°C under a 12/12 h light/dark cycle and had free access to food and water.

Construction of compressive SCI model

The compressive SCI model was established as previously described. Briefly, the rats were anesthetized by intraperitoneal injection of 1% sodium pentobarbital (50 mg/kg). The dorsal midline (about 30–40 mm) of rats was incised and the spinal cord was exposed at the position of the T8 vertebra using a bilateral laminectomy without damage to the dura. The vertebral column was then fixed and a metal rod was placed onto the spinal cord to make the compression injury. The tip of the rod was covered with a plastic plate, which was perpendicular to the longitudinal axis of spinal cord, and attached the dura surface. A metal tube was used to hold the rod and was then moved down vertically at a speed of 0.5 mm/min via connection with the stereotaxic apparatus to produce compression onto the spinal cord. After 5 min, the plastic plate was reached to the bottom of the vertebral canal and the rod was remained here for 1 min, followed by a slow withdraw within 1 min. Over the vertebral column, the wound was closed by suturing muscles and skin. The rats were kept in cages and the urinary bladder was manual evacuated twice daily.

Collection of spinal cord segment-derived CM

The central lesion of each spinal cord was distinguished macroscopically at the Th8–Th9 level. From the rostral (Th2–Th6), central lesion (Th7–Th11), and caudal (Th12–L3) segments to the site of injury, approximately 1.0 cm of samples were taken out and then cut into three 0.3-cm – thick sections per segment. These samples were then seeded on a 12-well culture plate containing DMEM without FBS. After 24-h incubation, CM obtained from SCI (CM-SCI) were collected (rostral, lesion, and caudal segments). The same procedure was performed for obtaining CM from control (CM-NC). Samples were subjected to trypsin digestion, desalted using C18 ziptips (Millipore), and dried under vacuum. Finally, samples were resuspended in water/5% acetonitrile/0.1% formic acid before use.

Cell culture

The murine microglial cell line BV2 was cultured on Poly-L-Ornithine-coated glass coverslips containing Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% fetal bovine serum (FBS) for 24 h and then treated with CM-SCI or CM-NC.

Lentivirus production and transduction

The flanking sequence of miRNA-128 and scrambled control were synthesized from GenePharma (Shanghai, China). To generate miRNA-128 and control lentivirus plasmid, the sequences of miRNA-128 and scrambled control were cloned into pMD18-T vector (Takara, Kyoto, Japan) and then subcloned into lentiviral vector pCDH-CMV-MCS-EF1-copGFP (System Bioscience, USA). The sequences of these recombinant plasmids were confirmed by gene sequencing. To generate lentivirus, the plasmids encoding miRNA-128 or scrambled control were cotransfected into 293T cells combined with the plasmids pHelper 1.0 and pHelper 2.0 (Genechem, Shanghai, China) using Lipofectamine 2000 (Invitrogen, CA) according to the manufacturer’s recommended protocol. To perform lentiviral transduction, the BV2 cells treated with CM-SCI or CM-NC were plated at 40–50% confluence and incubation was continued overnight.

MTT assay

Cells in logarithmic growth phase were adjusted to 5×104/mL and then cultured in a 96-well plate at 37°C in an atmosphere with 5% CO2. After transfection for 24, 48, and 72 h, 20 μL of fresh medium with 0.5 mg/mL MTT was added into each well to incubate for another 4 h before termination. Then, 200 μL dimethyl sulfoxide (DMSO) was added into each well. Optical density (OD) values for each well at 492 nm were measured with an Infinite M200 device (Tecan, Mannedorf, Switzerland). Each sample was tested 3 times.

Enzyme-linked immunosorbent assay (ELISA)

After transfection of 24 h, the media were removed from each culture well for quantitation of tumor-necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and IL-6. Concentrations of these secreted cytokines were then measured using commercially available mouse colorimetric sandwich ELISA plates (R&D Systems, Minneapolis, MN) following the recommend protocols of the manufacturer.

Quantitative real-time PCR (qRT-PCR)

Total RNA were extracted from treated cells using Trizol reagent (Invitrogen) in accordance with the manufacturer’s instructions. Then, 2 μg total RNA was reverse-transcribed to cDNA using reverse transcriptase (iScript™ cDNA Synthesis Kit; Bio-Rad Laboratories). The SYBR green-based qRT-PCR was then performed to detect the relative expression level of miR-128. Expression of U6 and β-actin was used as an endogenous control for miR-128. The primers used in our study were: miR-128, sense: 5′-ACACTCCAGCTGGGTCACAGTGAACCGGTC-3′, anti-sense: 5′-TGGTGTCGTGGAGTCG-3′; U6, sense: 5′-CTCGCT TCGGCAGCACA-3′, anti-sense: 5′-AACGCTTCACGAATTTGCGT-3′. The relative expression of targets was calculated using the method of comparative threshold (Ct) cycle (2−ΔΔCt), as previously described. All the qRT-PCR reactions were performed in triplicate.

Western blot analysis

Cells were lysed using radioimmunoprecipitation assay (RIPA) buffer (Roche, Basel, Switzerland). After protein concentrations were tested with Bradford (Bio-Rad, Madrid, Spain), the same concentration of protein samples was separated with 10–12% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and blotted onto polyvinylidene difluoride (PVDF) membranes. After blocking with PBST (0.1% triton in 19 PBS), the membrane was probed with anti-P38 antibody (Rabbit, SC7149, 1:200, Santa Cruz Co., CA), and anti-P-p38antibody (Rabbit, SC-101759, 1: 400) overnight at 4°C. The membranes were then probed with the secondary antibody, Abexcel (anti-rabbit, Abcam, 1:1000), for 2 h at room temperature. The expression of GAPDH was used as a loading control. The protein bands were developed by enhanced chemiluminescence and analyzed using use of ImageQuant software (Molecular Dynamics, Sunnyvale, CA).

Statistical analysis

Statistical analyses were performed with SPSS version 19.0 (SPSS Inc, Chicago, IL). All experimental data are presented as the mean ±SD. The normal distribution assessed with the one-sample K-S test, after which the P-values were calculated using one-way ANOVA or t-test. A statistically significant difference was defined at P<0.05.

Results

The expression of miR-128 was downregulated by CM-SCI

To determine whether miR-128 plays a role in NNP, BV2 cells were treated with CM-SCI or CM-NC, and then the mRNA level expression of miR-128 was monitored by RT-PCR analysis. As shown in Figure 1, the expression of miR-128 in BV2 cells treated with CM-SCI was significantly lower than that in BV2 cells or BV2 cells treated with CM-NC (P<0.05).
Figure 1

RT-PCR analysis showed the expression of miR-128 in BV2 cells treated with CM-SCI or CM-NC. The results are presented as the mean ±SD. * P<0.05.

Next, to further confirm the relationship between CM-SCI treatment and the expression of miR-128, BV2 cells were first treated with CM-SCI or CM-NC, and transfected with miRNA-128 or control vector, then the expression level of miR-128 was measured by RT-PCR analysis again (Figure 2). CM-NC The results showed that the expression of miR-128 was significantly downregulated by CM-SCI, and transfection with miR-128 vector can weaken its down-regulative effect (P<0.05). In addition, the expression of miR-128 in the CM-NC+vector group was significantly higher than that in the CM-SCI+vector group, and transfection with miR-128 significantly enhanced this up-regulative effect (P<0.05). These results indicate that miR-128 was successfully overexpressed.
Figure 2

RT-PCR analysis showed the expression of miR-128 in BV2 cells first transfected with miRNA-128 or control vector, and then treated with CM-SCI or CM-NC. The results are presented as the mean ±SD. * P<0.05.

Overexpression of miR-128 promoted cell viability

Cell viability was also evaluated by MTT assay after miR-128 overexpression. As shown in Figure 3, we found that the cell viability was significantly increased by miR-128 overexpression (P<0.05) in a time-dependent manner. These data indicate that overexpression of miR-128 can significantly promote cell viability.
Figure 3

MTT assay showed the cell viability of BV2 cells after transduction of miRNA-128 or control vector in an experimental period of 72 h. The results are presented as the mean ±SD. * P<0.05.

Overexpression of miR-128 altered M1/M2 microglial gene expression

To detect whether miR-128 overexpression affected microglial M1 and M2 phenotypes, the expression levels of microglial phenotypic markers CD86, CD32, Arg1, and CD206 were determined. Figure 4 shows that the expression levels of microglial M1 phenotypic markers, including CD86 and CD32, were significantly decreased in the CM-SCI+miR-128 group in comparison with that in the CM-SCI group or the CM-SCI+vector group (P<0.05), while the expression levels of microglial M2 phenotypic markers, such as CD86 and CD32, were markedly increased (P<0.05).
Figure 4

RT-PCR analysis showed the expressions of microglial phenotypic markers CD86, CD32, Arg1, and CD206 after transduction of miRNA-128 or control vector. The results are presented as the mean ±SD. * P<0.05.

Overexpression of miR-128 decreased the concentration of TNF-α, IL-1β and IL-6

We further detected the concentration of inflammatory cytokines TNF-α, IL-1β and IL-6 to verify whether miR-128 function is a critical mediator in the regulation of neuroinflammation. The results of ELISA in Figure 5 show that the concentrations of TNF-α, IL-1β, and IL-6 were all significantly decreased after miR-128 overexpression (P<0.05).
Figure 5

ELISA showed the concentration of TNF-α, IL-1β and IL-6 after transduction of miRNA-128 or control vector. The results are presented as mean ±SD. * P<0.05.

Overexpression of miR-128 downregulated the expression of P38 and phosphorylated P38 (P-P38)

To further investigate the possible mechanism of miR-128 in the development of NPP, the expression levels of P38 and P-P38 were explored (Figure 6). The results showed that the expression levels of P38 and P-P38 proteins were significantly decreased in the CM-SCI+miR-128 group compared with the CM-SCI group or the CM-SCI+vector group (P<0.05)
Figure 6

Western bolt analysis of the expression levels of P38 and P-P38 after transduction of miRNA-128 or control vector. The results are presented as mean ±SD. GAPDH was used as internal control. * P<0.05.

Discussion

MiR-128 is a neuronal enriched miRNA, whose expression is correlated with central nervous system development [16,17]. MiR-128 is also reported to be dysregulated in neurodegenerative disease [18]. The present study is the first to show the crucial roles of miR-128 in the regulation of NPP following SCI. We found that miR-128 was downregulated in murine microglial cells following SCI. In addition, overexpression of miR-128 promoted the viability of murine microglial cells, facilitated the activation of microglial M2 phenotype, and decreased the concentration of TNF-α, IL-1β and IL-6. We found that miR-128 overexpression significantly downregulated the expression levels of P38 and P-P38, suggesting the regulatory roles of P38 activation in miR-128-mediated NPP development. Collectively, these findings suggest that miR-128 may be a key regulator of NPP development. Emerging evidence has confirmed the critical role of microglia in the pathogenesis of NPP [19]. It has been confirmed that there are 2 functional subtypes of macrophages/microglia in the injured spinal cord: pro-inflammatory (M1 phenotype) and anti-inflammatory (M2 phenotype) macrophages/microglia. M2 activation is transient in the injured spinal cord following SCI [20], suggesting that M2 activation facilitates tissue repair via inflammatory responses following SCI. Jetten et al. demonstrated that M2 macrophages have higher angiogenic potential than M1 macrophages [21]. In our study, miR-128 was downregulated in murine microglial cells following SCI, and overexpression of miR-128 promoted the viability of murine microglial cells and increased the expression levels of M2 phenotypic markers Arg1 and CD206. Although the roles of miR-128 in microglia are unclear, we speculate that down-regulation of miR-128 may promote NPP development following SCI via suppressing the activation of microglial M2 phenotype. In addition, we found that miR-128 overexpression significantly decreased the concentration of inflammatory cytokines such as TNF-α, IL-1β, and IL-6. Inflammatory cytokines are key mediators of NPP. TNF-α is an NPP-related cytokine and plays a role in the peripheral mediation of NPP [22]. Silencing of TNF-α in dorsal root ganglia can reduce neuronal cell death and relieve the pathogenesis of NPP [23]. Intraneural injection of TNF-α and IL-1β into rat sciatic nerves can effectively induce signs of NPP [24]. The increased IL-6 in dorsal root ganglial neurons and spinal cord is also shown to result in the development of NPP following motor fiber injury [25]. Previous studies have demonstrated the strong correlation between NPP and neuroinflammation [26,27]. Taken together, these results suggest that miR-128 may be involved in NPP development via regulating the expression of inflammatory cytokines. Furthermore, activation of p38 mitogen-activated protein kinase (MAPK) in spinal microglia has been shown to be the key mechanism involved in the pathogenesis of NPP following spinal cord injury [28,29]. It has been reported that brain-derived neurotrophic factor (BDNF) secreted from spinal microglia leads to the development of NPP, possibly via activation of the p38-MAPK system [30,31]. In addition, TNF-α can trigger mechanical allodynia after spinal nerve ligation (SNL) through activation of p38-MAPK [32]. Activation of p38 in microglia can contribute to the increased concentration of pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6 [33]. To further explore the potential regulatory mechanism of miR-128, we investigated the expression of P38 and P-P38. We found that miR-128 overexpression significantly downregulated the expression levels of P38 and P-P38. In addition to the results that miR-128 overexpression significantly decreased the concentration of inflammatory cytokines such as TNF-α, IL-1β, and IL-6, it is intriguing to speculate that activation of P38 in murine microglial cells may be the key mechanism mediating the roles of miR-128 in the development of NPP following SCI.

Conclusions

Our findings indicate that down-regulation of miR-128 in murine microglial cells may contribute to the development of NPP following SCI via activation of P38. MiR-128 may be a potential intervention target for NPP. However, the precise role of miR-128 in the regulation of NPP needs to be verified.
  32 in total

1.  A microRNA array reveals extensive regulation of microRNAs during brain development.

Authors:  Anna M Krichevsky; Kevin S King; Christine P Donahue; Konstantin Khrapko; Kenneth S Kosik
Journal:  RNA       Date:  2003-10       Impact factor: 4.942

Review 2.  Chemokines and cytokines in neuroinflammation leading to neuropathic pain.

Authors:  Norikazu Kiguchi; Yuka Kobayashi; Shiroh Kishioka
Journal:  Curr Opin Pharmacol       Date:  2011-10-21       Impact factor: 5.547

3.  Spinal inhibition of p38 MAP kinase reduces inflammatory and neuropathic pain in male but not female mice: Sex-dependent microglial signaling in the spinal cord.

Authors:  Sarah Taves; Temugin Berta; Da-Lu Liu; Sophie Gan; Gang Chen; Yong Ho Kim; Thomas Van de Ven; Stefan Laufer; Ru-Rong Ji
Journal:  Brain Behav Immun       Date:  2015-10-19       Impact factor: 7.217

4.  Change in microRNAs associated with neuronal adaptive responses in the nucleus accumbens under neuropathic pain.

Authors:  Satoshi Imai; Mai Saeki; Makoto Yanase; Hiroshi Horiuchi; Minako Abe; Michiko Narita; Naoko Kuzumaki; Tsutomu Suzuki; Minoru Narita
Journal:  J Neurosci       Date:  2011-10-26       Impact factor: 6.167

Review 5.  MicroRNAs as modulators and biomarkers of inflammatory and neuropathic pain conditions.

Authors:  Hjalte H Andersen; Meg Duroux; Parisa Gazerani
Journal:  Neurobiol Dis       Date:  2014-08-10       Impact factor: 5.996

Review 6.  Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment.

Authors:  Ralf Baron; Andreas Binder; Gunnar Wasner
Journal:  Lancet Neurol       Date:  2010-08       Impact factor: 44.182

Review 7.  Neuropathic pain: a maladaptive response of the nervous system to damage.

Authors:  Michael Costigan; Joachim Scholz; Clifford J Woolf
Journal:  Annu Rev Neurosci       Date:  2009       Impact factor: 12.449

8.  Activation of p38 MAP kinase is involved in central neuropathic pain following spinal cord injury.

Authors:  Eric D Crown; Young Seob Gwak; Zaiming Ye; Kathia M Johnson; Claire E Hulsebosch
Journal:  Exp Neurol       Date:  2008-06-12       Impact factor: 5.330

9.  Up-regulation of P2X4 receptors in spinal microglia after peripheral nerve injury mediates BDNF release and neuropathic pain.

Authors:  Lauriane Ulmann; Jon P Hatcher; Jane P Hughes; Séverine Chaumont; Paula J Green; François Conquet; Gary N Buell; Alison J Reeve; Iain P Chessell; Francois Rassendren
Journal:  J Neurosci       Date:  2008-10-29       Impact factor: 6.167

10.  A miRNA signature of prion induced neurodegeneration.

Authors:  Reuben Saba; Chelsey D Goodman; Rhiannon L C H Huzarewich; Catherine Robertson; Stephanie A Booth
Journal:  PLoS One       Date:  2008-11-06       Impact factor: 3.240

View more
  17 in total

Review 1.  MicroRNAs in the Spinal Microglia Serve Critical Roles in Neuropathic Pain.

Authors:  Simin Tang; Huan Jing; Fuhu Song; Haicheng Huang; Wenjun Li; Guiling Xie; Jun Zhou
Journal:  Mol Neurobiol       Date:  2020-09-09       Impact factor: 5.590

2.  Protective role of microRNA-219-5p inhibitor against spinal cord injury via liver receptor homolog-1/Wnt/β-catenin signaling pathway regulation.

Authors:  Jie Li; Liqiang Li; Yong Shen
Journal:  Exp Ther Med       Date:  2018-02-01       Impact factor: 2.447

3.  Repair mechanism of astrocytes and non-astrocytes in spinal cord injury.

Authors:  Xiang-Yun Liu; Jian-Wei Guo; Jian-Qiang Kou; Yuan-Liang Sun; Xiu-Jun Zheng
Journal:  World J Clin Cases       Date:  2020-03-06       Impact factor: 1.337

Review 4.  MicroRNAs Instruct and Maintain Cell Type Diversity in the Nervous System.

Authors:  Norjin Zolboot; Jessica X Du; Federico Zampa; Giordano Lippi
Journal:  Front Mol Neurosci       Date:  2021-04-29       Impact factor: 5.639

Review 5.  Epigenetics Control Microglia Plasticity.

Authors:  Mathilde Cheray; Bertrand Joseph
Journal:  Front Cell Neurosci       Date:  2018-08-03       Impact factor: 5.505

6.  LncRNA MALAT1 promotes neuropathic pain progression through the miR‑154‑5p/AQP9 axis in CCI rat models.

Authors:  Jianping Wu; Chuanguang Wang; Haiyang Ding
Journal:  Mol Med Rep       Date:  2019-11-20       Impact factor: 2.952

7.  Prognosis Evaluation Using 18F-Alfatide II PET in a Rat Model of Spinal Cord Injury Treated With Estrogen.

Authors:  Hongpei Tan; Yongxiang Tang; Jian Li; Tingting He; Ming Zhou; Shuo Hu
Journal:  Mol Imaging       Date:  2020 Jan-Dec       Impact factor: 4.488

Review 8.  Neuroinflammation in Ischemic Stroke: Focus on MicroRNA-mediated Polarization of Microglia.

Authors:  Lu Lian; Yunsha Zhang; Lu Liu; Liji Yang; Yichen Cai; Junping Zhang; Shixin Xu
Journal:  Front Mol Neurosci       Date:  2021-01-07       Impact factor: 5.639

Review 9.  The Regulatory Mechanisms and Therapeutic Potential of MicroRNAs: From Chronic Pain to Morphine Tolerance.

Authors:  Zhao Dai; Haichen Chu; Jiahai Ma; Ying Yan; Xueying Zhang; Yongxin Liang
Journal:  Front Mol Neurosci       Date:  2018-03-16       Impact factor: 5.639

Review 10.  Central Neuropathic Mechanisms in Pain Signaling Pathways: Current Evidence and Recommendations.

Authors:  Omar Viswanath; Ivan Urits; James Burns; Karina Charipova; Kyle Gress; Alexandra McNally; Richard D Urman; Ali Welschmeyer; Amnon A Berger; Hisham Kassem; Manuel G Sanchez; Alan D Kaye; Treniece N Eubanks; Elyse M Cornett; Anh L Ngo
Journal:  Adv Ther       Date:  2020-04-10       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.